AR085616A1 - Composicion farmaceutica inhalable que comprende glicopirrolato, uso - Google Patents
Composicion farmaceutica inhalable que comprende glicopirrolato, usoInfo
- Publication number
- AR085616A1 AR085616A1 ARP120100709A ARP120100709A AR085616A1 AR 085616 A1 AR085616 A1 AR 085616A1 AR P120100709 A ARP120100709 A AR P120100709A AR P120100709 A ARP120100709 A AR P120100709A AR 085616 A1 AR085616 A1 AR 085616A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- glicopirrolate
- inhalable pharmaceutical
- composition understanding
- understanding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Abstract
Reivindicación 1: Una composición farmacéutica inhalable que comprende glicopirrolato o una sal del mismo farmacéuticamente aceptable para utilizar como un agente reductor de la frecuencia cardiaca.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1103770.2A GB201103770D0 (en) | 2011-03-04 | 2011-03-04 | Novel use |
GBGB1202256.2A GB201202256D0 (en) | 2012-02-09 | 2012-02-09 | Novel use |
Publications (1)
Publication Number | Publication Date |
---|---|
AR085616A1 true AR085616A1 (es) | 2013-10-16 |
Family
ID=45841526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120100709A AR085616A1 (es) | 2011-03-04 | 2012-03-05 | Composicion farmaceutica inhalable que comprende glicopirrolato, uso |
Country Status (20)
Country | Link |
---|---|
US (2) | US20140080890A1 (es) |
EP (1) | EP2680841B1 (es) |
JP (1) | JP6129081B2 (es) |
KR (1) | KR101853997B1 (es) |
CN (1) | CN103501781B (es) |
AR (1) | AR085616A1 (es) |
AU (1) | AU2012226608B2 (es) |
BR (1) | BR112013022523A2 (es) |
CA (1) | CA2828640C (es) |
CL (1) | CL2013002542A1 (es) |
EA (1) | EA025287B1 (es) |
ES (1) | ES2613754T3 (es) |
GE (1) | GEP201706640B (es) |
IL (1) | IL227972A (es) |
JO (1) | JO3510B1 (es) |
MD (1) | MD4369C1 (es) |
MX (1) | MX356025B (es) |
TW (1) | TWI536988B (es) |
WO (1) | WO2012120284A1 (es) |
ZA (1) | ZA201306130B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9463161B2 (en) | 2009-05-29 | 2016-10-11 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
AU2013100009B4 (en) * | 2013-01-04 | 2013-03-14 | Novartis Ag | Treatment of chronic obstructive pulmonary disease |
AU2013100007B4 (en) * | 2013-01-04 | 2013-05-23 | Novartis Ag | System for treating chronic obstructive pulmonary disease |
JP6454323B2 (ja) * | 2013-03-15 | 2019-01-16 | パール セラピューティクス,インコーポレイテッド | 粒子状結晶性材料のコンディショニングのための方法及びシステム |
RS60299B1 (sr) | 2014-09-09 | 2020-07-31 | Vectura Ltd | Formulacija koja obuhvata glikopirolat, postupak i uređaj |
WO2016071862A1 (en) * | 2014-11-05 | 2016-05-12 | Glenmark Pharmaceuticals Limited | Inhalable pharmaceutical composition comprising glycopyrronium |
JP6655169B2 (ja) | 2015-09-09 | 2020-02-26 | ベクトゥラ・リミテッド | ジェット粉砕法 |
PL3248646T3 (pl) * | 2016-05-25 | 2021-08-16 | Claudia Mattern | Dwuczęściowy zestaw półfabrykatu z tworzywa sztucznego |
PT109445B (pt) * | 2016-06-08 | 2018-11-06 | Hovione Farm Sa | Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose |
WO2018167180A1 (en) * | 2017-03-15 | 2018-09-20 | Vectura Limited | Method and formulation |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
BE718438A (es) * | 1967-08-23 | 1968-12-31 | ||
NL8104929A (nl) * | 1980-11-12 | 1982-06-01 | Alza Corp | Anticholinergische preparaten, alsmede de bereiding en de toepassing ervan. |
GB9501841D0 (en) * | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
EP0909163A4 (en) * | 1996-07-01 | 1999-06-09 | Sepracor Inc | METHOD AND MEANS FOR TREATING URINE INCONTINENCE USING THE (S, R) -GLYCOPYRROLATE ENANTIOMER MAINLY |
GB9808470D0 (en) * | 1998-04-22 | 1998-06-17 | Smithkline Beecham Plc | Novel process and apparatus |
KR20000013487A (ko) * | 1998-08-10 | 2000-03-06 | 정주영 | 글리코피롤레이트를 유효성분으로 하는 근시예방 및 치료용 조성물 |
EP1862164A3 (de) | 1998-11-13 | 2012-12-26 | Jagotec AG | Trockenpulver zur Inhalation |
GB9826284D0 (en) | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
GB9826286D0 (en) * | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
DE19921693A1 (de) * | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
DE10136404A1 (de) * | 2001-07-26 | 2003-02-20 | Johannes Wohlrab | Arzneiformulierung zur topischen Anwendung für die Therapie und Prophylaxe von Hyperhidrosis |
CA2384922C (en) * | 2002-05-03 | 2008-09-02 | Purepharm Inc. | Topical glycopyrrolate product for the reduction of sweating |
GB0326632D0 (en) | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
JP5524442B2 (ja) * | 2004-02-06 | 2014-06-18 | メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 呼吸器疾患の治療のための、抗コリン作用薬及びβ−模倣薬の新規併用薬 |
GB0409703D0 (en) * | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
GB0410399D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
GB0410398D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
US7923455B2 (en) | 2005-01-28 | 2011-04-12 | Boehringer Ingelheim International Gmbh | Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic |
GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
EP1894568A1 (en) | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
GB0703999D0 (en) * | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | New combination 667 |
US20080260823A1 (en) * | 2007-04-20 | 2008-10-23 | Sciele Pharma, Inc. | Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea |
US20100055045A1 (en) | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
WO2010144628A2 (en) | 2009-06-09 | 2010-12-16 | Elevation Pharmaceuticals, Inc. | Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration |
-
2012
- 2012-02-26 JO JOP/2012/0040A patent/JO3510B1/ar active
- 2012-03-02 TW TW101106929A patent/TWI536988B/zh active
- 2012-03-05 MD MDA20130069A patent/MD4369C1/ro active IP Right Grant
- 2012-03-05 EA EA201391275A patent/EA025287B1/ru not_active IP Right Cessation
- 2012-03-05 MX MX2013009838A patent/MX356025B/es active IP Right Grant
- 2012-03-05 CN CN201280021503.6A patent/CN103501781B/zh active Active
- 2012-03-05 CA CA2828640A patent/CA2828640C/en active Active
- 2012-03-05 JP JP2013557170A patent/JP6129081B2/ja active Active
- 2012-03-05 AR ARP120100709A patent/AR085616A1/es unknown
- 2012-03-05 US US14/002,466 patent/US20140080890A1/en not_active Abandoned
- 2012-03-05 AU AU2012226608A patent/AU2012226608B2/en active Active
- 2012-03-05 ES ES12709151.0T patent/ES2613754T3/es active Active
- 2012-03-05 WO PCT/GB2012/050478 patent/WO2012120284A1/en active Application Filing
- 2012-03-05 GE GEAP201213251A patent/GEP201706640B/en unknown
- 2012-03-05 EP EP12709151.0A patent/EP2680841B1/en active Active
- 2012-03-05 KR KR1020137025861A patent/KR101853997B1/ko active IP Right Grant
- 2012-03-05 BR BR112013022523A patent/BR112013022523A2/pt not_active Application Discontinuation
-
2013
- 2013-08-15 ZA ZA2013/06130A patent/ZA201306130B/en unknown
- 2013-08-15 IL IL227972A patent/IL227972A/en active IP Right Grant
- 2013-09-04 CL CL2013002542A patent/CL2013002542A1/es unknown
-
2016
- 2016-01-31 US US15/011,582 patent/US10695321B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR085616A1 (es) | Composicion farmaceutica inhalable que comprende glicopirrolato, uso | |
ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
CR20150114A (es) | Composición farmacéutica recubierta que contiene regorafenib | |
ECSP12011930A (es) | Nuevos compuestos de espiropiperidina | |
CY1119798T1 (el) | Μορφη iv υδροχλωρικης ιβαμπραδινης | |
MX365939B (es) | Moduladores del transporte nuclear y usos de los mismos. | |
RS54873B1 (sr) | Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba | |
NZ702663A (en) | Nuclear transport modulators and uses thereof | |
MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
AR082381A1 (es) | Composicion acuosa que contiene bromhexina | |
CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
AR077629A1 (es) | Mimetico de smac | |
EA201400771A1 (ru) | Новые производные азетидина, фармацевтические композиции и их применение | |
UY32153A (es) | Inhibidores de piridomidinona de pi13ka(alfa) y mtor | |
BR112012032008A2 (pt) | anticorpos s100a4 e usos terapêuticos do mesmo | |
CL2014000552A1 (es) | Uso de 4,4´-[fluoro-(1h-1,2,4-triazol-1-il)metileno]bisbenzonitrilo para el tratamiento del hipogonadismo y composicion farmaceutica oral que comprende al compuesto y kit farmaceutico que comprende a la composicion. | |
AR090073A1 (es) | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos | |
AR090975A1 (es) | N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida | |
UY32414A (es) | Nuevos metodos | |
UY31768A (es) | Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre | |
AR091888A1 (es) | Compuestos de urea y su uso como inhibidores de enzimas | |
CR20130532A (es) | Aclidinio para uso en la mejora de la calidad del sueño en pacientes respiratorios | |
GB201105050D0 (en) | Pharmaceutical agent | |
AR094063A1 (es) | Uso de aclidinio, composicion farmaceutica y metodo para mejorar la actividad fisica en pacientes respiratorios |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |